Cetera Advisor Networks’s Sarepta Therapeutics SRPT Stock Holding History

Cetera Advisor Networks’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,075	Closed	-$528K	–	2668
2022 Q4	$528K	Buy	+4,075	New	+$472K	﹤0.01%	1601
2021 Q3	–	Sell	-3,220	Closed	-$250K	–	2041
2021 Q2	$250K	Buy	3,220 +130	+4%	+$9.86K	﹤0.01%	1625
2021 Q1	$230K	Buy	+3,090	New	+$285K	﹤0.01%	1297
2020 Q3	–	Sell	-828	Closed	-$133K	–	2795
2020 Q2	$133K	Buy	+828	New	+$113K	﹤0.01%	1346
2014 Q3	–	Sell	-8,470	Closed	-$249K	–	853
2014 Q2	$249K	Sell	8,470 -2,505	-23%	-$79.2K	0.02%	669
2014 Q1	$259K	Sell	10,975 -50	-0.5%	-$1.27K	0.02%	624
2013 Q4	$222K	Sell	11,025 -7,980	-42%	-$237K	0.02%	656
2013 Q3	$893K	Sell	19,005 -3,075	-14%	-$118K	0.08%	253
2013 Q2	$844K	Buy	+22,080	New	+$790K	0.08%	229

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Advisor Networks's SRPT Position: Q1 2023 in Review

Cetera Advisor Networks sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 4,075 shares — an estimated $528K sold.

Cetera Advisor Networks first reported a position in SRPT in Q2 2013 and held it in 9 quarters. The position peaked at $893K in Q3 2013. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

Cetera Advisor Networks reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
Cetera Advisor Networks sold 4,075 Sarepta Therapeutics shares in Q1 2023, an estimated $528K.
Cetera Advisor Networks first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 9 quarters.
Cetera Advisor Networks's Sarepta Therapeutics position peaked at $893K in Q3 2013.
425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on Cetera Advisor Networks's 13F filing for Q1 2023, filed 15 May 2023.